Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Nashville, Tennessee

CNS medication trials in Nashville, TN

23 CNS medication studies are recruiting participants at sites in Nashville as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Nashville at a glance

  • 23 studies are recruiting at a site in Nashville.
  • By phase: Early Phase 1 (1), Phase 1 (1), Phase 2 (4), Phase 3 (15), Phase 4 (2).
  • By sponsor: industry (18), university, hospital or other (5).
  • By research area: Parkinson's Disease (8), Migraine (6), Epilepsy (5), Schizophrenia (2), Depression (1), Multiple Sclerosis (1).
  • Most recent update to one of these records: November 17, 2026.

Depression studies recruiting in Nashville

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Yale University
    Study site
    Athena Care
    Registry record
    NCT06713616 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Nashville, TN on ClinicalTrials.gov.

Schizophrenia studies recruiting in Nashville

  1. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Access Clinical Trials
    Registry record
    NCT06229210 · updated
  2. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Vanderbilt Psychiatric Hospital
    Registry record
    NCT06585787 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Nashville, TN on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Nashville

  1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Elliston Place Medical Oncology & Hematology ( Site 0215)
    Registry record
    NCT06623422 · updated
  2. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    SCRI Oncology Partners ( Site 7004) · Tennessee Oncology ( Site 0018)
    Registry record
    NCT06841354 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Nashville General Hospital ( Site 0017) · SCRI Oncology Partners ( Site 7005) · Vanderbilt-Ingram Cancer Center ( Site 0038)
    Registry record
    NCT06966700 · updated
  4. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT07174310 · updated
  5. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    Vanderbilt University
    Registry record
    NCT06680830 · updated
  6. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    • Phase 2
    • Ages 30 to 80
    • All sexes
    Sponsor
    Appello Pharmaceuticals, Inc.
    Study site
    Vanderbilt University Medical Center (Site #204)
    Registry record
    NCT07432958 · updated
  7. Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

    • Phase 4
    • Ages 50 to 85
    • All sexes
    Sponsor
    Vanderbilt University Medical Center
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT05357612 · updated
  8. [18F]F-DOPA Imaging in Patients With Autonomic Failure

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Daniel Claassen
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT04246437 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Nashville, TN on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Nashville

  1. A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Vanderbilt Breast Center at One Hundred Oaks
    Registry record
    NCT07225504 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Nashville, TN on ClinicalTrials.gov.

Epilepsy studies recruiting in Nashville

  1. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Registry record
    NCT07594119 · updated
  2. A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT05716100 · updated
  3. RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT06798896 · updated
  4. Effect of Rose Odor Exposure on Ictal Apnea

    • Early Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Vanderbilt University Medical Center
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT07116421 · updated
  5. A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT07219407 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Nashville, TN on ClinicalTrials.gov.

Migraine studies recruiting in Nashville

  1. Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

    • Phase 4
    • Ages 18 to 70
    • All sexes
    Sponsor
    Mayo Clinic
    Study site
    Vanderbilt Medical Center
    Registry record
    NCT06972056 · updated
  2. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Access Clinical Trials, Inc · Clinical Research Associates, Inc.
    Registry record
    NCT07645924 · updated
  3. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Access Clinical Trials Inc · Clinical Research Associates, Inc.
    Registry record
    NCT07674654 · updated
  4. A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Access Clinical Trials Inc /ID# 270280
    Registry record
    NCT06810505 · updated
  5. A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Access Clinical Trials, Inc. /ID# 248532
    Registry record
    NCT05711394 · updated
  6. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Access Clinical Trials, Inc. /ID# 228002
    Registry record
    NCT05125302 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Nashville, TN on ClinicalTrials.gov.

Ask about studies near Nashville

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call